Lanraplenib
As of the edition of 20 October 2026, Lanraplenib is a small molecule: stopped in 2024; acts on SYK.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 5, 1 stopped early
- Disease areas
- Skin and connective tissue; Blood and lymph; Bones, joints and muscles; Cancer; Eye; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Lanraplenib.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SYK | Tyrosine-protein kinase SYK | P43405 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 3 | 0 | 1 |
| All trials | 5 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Gilead Sciences | Lead sponsor of trials | 2016 to now |
| Concentra Biosciences | Lead sponsor of trials | 2022 to now |